<DOC>
	<DOCNO>NCT01386671</DOCNO>
	<brief_summary>The aim study compare efficacy safety Metformin Glycinate versus Metformin Hydrochloride metabolic control inflammatory mediator Mexican drug naïve type 2 diabetes patient , 12 month follow .</brief_summary>
	<brief_title>Metformin Glycinate Metabolic Control Inflammatory Mediators Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes accord ADA Less year evolution since diagnosis Antihyperglycemic pharmacological treatment HbA1c 7.1 % 9.0 % Stable weight last 6 month Body Mass Index ≥ 25 kg/m2 &lt; 35kg/m2 . Blood pressure ≤ 130/80 mmHg Childbearing woman contraceptive treatment Signed Informed Consent Form Age 18 70 year old Nonfulfilment treatment screen period Drugs alcohol abuse Creatinine depuration estimate MDRD formula use serum creatinine &lt; 90 ml/min/1.72m2 History chronic liver disease , ALT AST ≥ 2 time normal superior limit , GGT ≥ 3 time normal superior limit . Chronic lung disease , cause dyspnea equivalent functional class ≥3 ( NYHA ) require oxygen supplementation . History symptoms coronary artery disease ( CAD ) cerebrovascular disease ( CVD ) . Drug treatment interact biguanides . Another chronic disease restrict survival associate chronic inflammation like : cancer , leukemia , lymphoma , erythematosus lupus , asthma , rheumatoid arthritis infection HIV . Pregnancy positive pregnancy test woman 50 year old breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>metformin glycinate</keyword>
	<keyword>metabolic control</keyword>
</DOC>